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Abstract 1 
Interpreting clinical changes during acute exacerbations of chronic obstructive 2 
pulmonary disease (AECOPD) is challenging due to the absence of established 3 
minimal detectable (MDD) and important (MID) differences for most respiratory 4 
measures. This study established MDD and MID for respiratory measures in 5 
outpatients with AECOPD following pharmacological treatment. 6 
COPD assessment test (CAT), modified Borg scale (MBS), modified British 7 
Medical Research Council questionnaire (mMRC), peripheral oxygen saturation 8 
(SpO2), computerised respiratory sounds and forced expiratory volume in one second 9 
(FEV1) were collected within 24-48h of an AECOPD and after 45 days of 10 
pharmacological treatment. MID and MDD were calculated using anchor- (ROC and 11 
linear regression analysis) and distribution-based methods (effect size, SEM, 0.5*SD 12 
and MDC95) and pooled using Meta XL.  13 
Forty-four outpatients with AECOPD (31♂; 68.2±9.1yrs; FEV1 14 
51.1±20.3%predicted) participated. Significant correlations with CAT were found for 15 
the MBS (r=0.34), mMRC (r=0.39) and FEV1 (r=0.33), resulting in MIDs of 0.8, 0.5-0.6 16 
and 0.03L, respectively. MDD of 0.5-1.4 (MBS), 0.4-1.2 (mMRC), 0.10-0.28L (FEV1), 17 
3.6-10.1% (FEV1%predicted), 0.9-2.4% (SpO2), 0.7-1.9 (number of inspiratory 18 
crackles), 1.1-4.5 (number of expiratory crackles), 7.1-25.8% (inspiratory wheeze rate) 19 
and 11.8-63.0% (expiratory wheeze rate) were found. 20 
Pooled data of MID/MDD showed that improvements of 0.9 for the MBS, 0.6 for 21 
the mMRC, 0.15L for the FEV1, 7.6% for the FEV1%predicted, 1.5% for the SpO2, 1.1 22 
for the inspiratory and 2.4 for the number of expiratory number of crackles, 14.1% for 23 
the inspiratory and 32.5% for the expiratory wheeze rate are meaningful following an 24 
AECOPD managed with pharmacological treatment on an outpatient basis. 25 
  26 
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Introduction 1 
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are 2 
frequent events during the course of COPD 1. Recovery from AECOPD can take up to 3 
91 days, and it is known that some patients may never fully recover to their baseline 4 
status 2. Additionally, costs associated with the management of AECOPD are 5 
estimated in $7.100 per patient, per exacerbation 3. These facts place AECOPD as 6 
the main responsible for patients’ clinical deterioration and increased healthcare costs 7 
in COPD 4. 8 
The health and economic burden of AECOPD demand timely and appropriate 9 
management of these events 5, and a significant amount of research is currently being 10 
conducted with this purpose 5,6. Nevertheless, the interpretation of improvements seen 11 
during the recovery from AECOPD remains difficult, due to the absence of minimal 12 
important differences (MID) for most respiratory measures used in the assessment 13 
and monitoring of these patients 7. 14 
MID, defined as a meaningful important change for patients, which would lead 15 
to consider a change in the patients’ management 8, is currently the standard to 16 
interpret results obtained, guide changes in patient’s treatments and to calculate 17 
sample sizes in clinical research. According to the authors best knowledge, MIDs for 18 
patients with AECOPD have been established mainly in inpatients 9,10 and for patient-19 
reported measures, such as the Clinical COPD Questionnaire 7, the Chronic 20 
Respiratory Disease Questionnaire 7 and the COPD Assessment Test (CAT) 10. This 21 
limits the management of patients treated on an outpatient basis, which correspond to 22 
more than 80% of AECOPD 11, and the interpretation of changes in other important 23 
and widely used clinical respiratory measures, such as peripheral oxygen saturation 24 
(SpO2), auscultation and lung function 7,12. Additionally, the interpretability of specific 25 
measures of dyspnoea, the most representative and valued symptom in patients 26 
presenting an AECOPD 2,13, is yet to be established. Incorrect interpretations of 27 
patients’ improvements in these outcomes may lead to the development of suboptimal 28 
therapies and ultimately increase the rate of patients’ deterioration. 29 
Thus, this study aimed to estimate the MID in outpatients with AECOPD for the 30 
following respiratory measures: modified Borg scale (MBS), modified British Medical 31 
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Research Council (mMRC) questionnaire, SpO2, computerised respiratory sounds, 1 
namely crackles and wheezes, and forced expiratory volume in one second (FEV1). 2 
Additionally, the minimal detectable difference (MDD), i.e., the minimal change in a 3 
specific measure that fall outside the measurement error 14, was also calculated for 4 
each outcome measure. 5 
Methods 6 
Study design and participants 7 
An observational study, part of a longitudinal study conducted in outpatients 8 
with AECOPD recruited from the urgent care of a Central hospital 15, was conducted. 9 
Inclusion criteria were diagnosis of an AECOPD according to the Global Initiative for 10 
Chronic Obstructive Lung Disease (GOLD) criteria 11. Exclusion criteria were 11 
hospitalisation (defined as the need to be admitted as an inpatient at the respiratory 12 
or intensive care unit for further assessment/treatment after consultation with the 13 
urgency physician), patients requiring emergency intubation, and/or mechanical 14 
ventilation; patients with compromised neurological status or hemodynamic instability 15 
or presence of severe co-existing respiratory, neurological (e.g., Parkinson disease), 16 
cardiac (e.g., uncontrolled symptomatic heart failure), musculoskeletal (e.g., 17 
kyphoscoliosis), or signs of psychiatric impairments. Eligible patients were identified 18 
by physicians and contacted by the researchers, who explained the purpose of the 19 
study and asked about their willingness to participate. An appointment with the 20 
researchers was scheduled within 48 hours of the hospital visit with those interested 21 
to participate. 22 
Approval for this study was obtained from the ethics committee of the Centro 23 
Hospitalar do Baixo Vouga (13NOV’1514:40065682) and from the National Data 24 
Protection Committee (8828/2016). Written informed consent, following the guidelines 25 
of the Declaration of Helsinki, was obtained from patients before any data collection. 26 
Data collection 27 
Patients were asked to attend to 4 assessment sessions: within 48 hours of the 28 
urgent care visit (T1 – exacerbation onset) and approximately 8 days (T2 – during 29 
exacerbation), 15 days (T3 – following exacerbation) 16 and 45 days after the hospital 30 
visit (T4 – at stability post exacerbation). Data collection occurred at the urgent care, 31 
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in the facilities of the Respiratory Research and Rehabilitation Laboratory (Lab3R) of 1 
the School of Health Sciences, University of Aveiro (Portugal) or at patients’ home.  2 
According to the time interval used in previous studies to establish minimal 3 
important differences for clinical measures in AECOPD (i.e., 14 days to 3 months) 4 
9,10,17,18, and to ensure patients’ stability after the AECOPD (defined according to 5 
patient’s reports of symptoms stability - i.e., no changes beyond their day-to-day 6 
variability, no visits to health care units and no changes in their medication in the month 7 
preceding the evaluation) 19, only data from T1 and T4 were explored.  8 
Sociodemographic (age, sex), anthropometric (height, weight and body mass 9 
index - BMI) and general clinical data (smoking habits, number of exacerbations in the 10 
past year, medication and activities related dyspnoea) were first collected.  11 
In each data collection moment, impact of the disease, dyspnoea at rest and 12 
during activities, SpO2, computerised respiratory sounds and lung function were 13 
collected by a trained physiotherapist following the described standardised order. 14 
Impact of the disease was measured with the CAT, a disease-specific 15 
questionnaire consisting of eight items (i.e., cough, sputum, chest tightness, 16 
breathlessness going up hills/stairs, activity limitations at home, confidence leaving 17 
home, sleep, and energy) scored from 0 to 5 20. Each item individual score is added 18 
to provide a total CAT score that can range from 0 to 40 20. Higher scores indicate 19 
more impact of the disease on patients’ life. CAT was chosen as the anchor to 20 
determine the MID of the respiratory measures since it reflects a global rating of impact 21 
in health, is responsive to change, and has a MID established for patients with 22 
AECOPD 10. 23 
Dyspnoea at rest was assessed with the MBS 21, and activity limitation due to 24 
dyspnoea was assessed using the mMRC questionnaire 22. The MBS is a categorical 25 
scale with a score from 0 to 10, where 0 corresponds to the sensation of normal 26 
breathing and 10 corresponds to the patients’ maximum possible sensation of 27 
dyspnoea 23. The mMRC questionnaire is a 5-point scale where level 0 represents the 28 
lowest level of dyspnoea impairment perceived and level 4 the greatest dyspnoea 29 
impairment 23. Both scales have been shown to be valid and reliable in patients with 30 
COPD 23,24. 31 
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Peripheral oxygen saturation was collected at rest with a pulse oximeter (Pulsox 1 
300i, Konica Minolta, Tokyo, Japan). This measure has been widely used to assess 2 
effectiveness of interventions in patients with AECOPD and has shown fair validity 3 
against arterial oxygen saturation (bias in the Bland and Altman of -0.78; 95% 4 
confidence interval – CI of 8.2 to 6.7) in this population 7. 5 
Computerised respiratory sounds, specifically the inspiratory and expiratory 6 
mean number of crackles and wheeze occupation rate, acquired at the posterior chest, 7 
were analysed. Respiratory sounds were acquired with air-coupled electret 8 
microphones (C 417PP, AKG Acoustics GmbH, Vienna, Austria) and a multi-channel 9 
audio interface (AudioBox 1818 VSL, PreSonus, Florida, USA) and were analysed 10 
with previous validated algorithms 25-27. Number of crackles and wheeze occupation 11 
rate acquired in posterior locations have been shown to be valid against lung function 12 
(-0.11<rs<-0.44) 28, reliable (0.25<ICC1,2<0.86) 28,29 and sensitive to changes in 13 
patients with stable and exacerbated COPD 15,30. Further details on respiratory sound 14 
acquisition and analysis have been provided elsewhere 31. 15 
Lung function was assessed with a portable spirometer (MicroLab 3535, 16 
CareFusion, Kent, UK) 32 according to international guidelines 33. FEV1 in litres and as 17 
percentage of predicted (FEV1 percentage predicted) were extracted for each patient. 18 
These parameters have been shown to be feasible, valid and reliable (ICC=0.89) to 19 
assess in patients with AECOPD 12. 20 
Statistical analysis 21 
All statistical analyses were performed using IBM SPSS Statistics version 25.0 22 
(IBM Corporation, Armonk, NY, USA) or Meta XL 5.3 (EpiGear International, 23 
Queensland, Australia). Plots were created using GraphPad Prism version 5.01 24 
(GraphPad Software, Inc., La Jolla, CA, USA) or Meta XL 5.3. The level of significance 25 
was set at 0.05. Descriptive statistics were used to describe the sample, and 26 
participants’ characteristics were expressed as relative frequencies, mean (standard 27 
deviation) or median (interquartile range) as appropriate. Outlier’s analysis was 28 
performed by plotting the studied variables (i.e. MBS, mMRC, SpO2, computerised 29 
respiratory sounds, FEV1 and FEV1 percentage predicted) against the CAT (i.e., the 30 
anchor used to compute the MID) on a graph and visually inspecting the graph for 31 
wayward (extreme) points 34. The outliers found were removed for both MID and MDD 32 
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analysis. Significance of changes between T1 and T4 was calculated with paired t-1 
tests or Wilcoxon signed-rank tests depending on normality. 2 
Minimal important difference 3 
MIDs were calculated through questionnaire referencing methods using CAT 4 
as an anchor. Then, changes in CAT were correlated with changes in MBS, mMRC, 5 
SpO2, inspiratory and expiratory mean number of crackles and wheeze occupation 6 
rate, FEV1 and FEV1 percentage predicted, using Pearson correlation coefficient, to 7 
determine suitability for its use as an anchor. Significant correlations equal or superior 8 
to 0.3 were considered suitable and used in further analysis to establish the MID 35. 9 
To discriminate patients who improved from those who did not improve their health 10 
status, the established MID in the CAT total score for patients with AECOPD (two 11 
points improvement) was used 10,18. MIDs were calculated using receiver operating 12 
characteristic (ROC) curves and linear regression analysis. For each ROC curve, the 13 
area under the curve (AUC) and 95% confidence intervals were obtained and the MID 14 
for each respiratory measure was chosen as the point where the sensitivity (SN) and 15 
specificity (SP) were simultaneously maximised (i.e., the data point closest to the 16 
upper left corner of the ROC curve) (Table 1). For linear regression analysis, the 17 
equations developed which reached statistical significance were used to estimate 18 
change in respiratory scores corresponding to the MID improvement for the CAT 19 
(Table 1). 20 
Minimal detectable difference 21 
Distribution-based methods used to calculate MDD were (1) effect sizes (34), 22 
interpreted as small (dz>0.2), medium (dz>0.5) or large (dz≥0.8) 36; (2) 0.5 times the 23 
standard deviation (SD) of the baseline session (33); (3) standard error of 24 
measurement (SEM) 37 and (4) minimal detectable change (MDC) at the 95% level of 25 
confidence 38 (Table 1). The intraclass correlation coefficient (ICC1,2) used for the SEM 26 
calculation was established based on the between-days reliability previously published 27 
by Sant'Anna, Donaria, Furlanetto, Morakami, Rodrigues, Grosskreutz, Hernandes, 28 
Gosselink, Pitta 39 for SpO2 (ICC3,1=0.89) and MBS (ICC3,1=0.95), Mahler, Ward, 29 
Waterman, McCusker, ZuWallack, Baird 40 for mMRC (ICC=0.82) and FEV1 30 
(ICC=0.96), and by Oliveira, Lage, Rodrigues, Marques 28 for number of crackles 31 
(inspiratory crackles ICC1,2=0.79; expiratory crackles ICC1,2=0.42) and wheeze 32 
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occupation rate (inspiratory wheezes ICC1,2=0.57; expiratory wheezes ICC1,2=0.07). 1 
The pooling of data was performed based on what has been previously described by 2 
Alma et al. (2006, 2008) 41,42. MIDs and MDD estimated with each of the anchor- and 3 
distribution-based methods for the MBS, mMRC, SpO2, inspiratory and expiratory 4 
mean number of crackles and wheeze occupation rate, FEV1, and FEV1 percentage 5 
predicted were pooled using Meta XL 5.3. The input data were the estimated 6 
MID/MDD with each method and respective confidence interval, when appropriated, 7 
being the output the same as the input. Given that anchor- are preferred over 8 
distribution-based methods for the establishment of clinically significance 35,43, a 9 
quality effects model 44 was used to incorporate the weight of each method in the 10 
pooled estimate, where anchor methods weighted more than distribution methods 42. 11 
Table 1. Anchor and distribution-based methods to estimate the minimal important and detectable 12 
differences. 13 
Method Approach Statistics 
Anchor-based method ROC curve - 
Linear regression 
analysis 
- 
Distribution-based method ES 
(𝑚𝑒𝑎𝑛𝑇4 − 𝑚𝑒𝑎𝑛𝑇1)/√(𝑆𝐷𝑇1
2 + 𝑆𝐷𝑇4
2 )/2 
0.5 times SD 0.5 × SDT1 
SEM SDT1 √(1 − ICC1,2 ) 
MDC95 MDC95 = SEM × 1.96 × √2 
ES, effect size; MDC95, minimal detectable change at the 95% level of confidence; ROC, receiver operator characteristics; SD, 14 
standard deviation; SEM, standard error of measurement. 15 
Results 16 
Participants 17 
Seventy-eight non-hospitalised patients with AECOPD were referred for 18 
possible inclusion in the study. Of these, 34 were excluded because, at T1, presented 19 
lung function tests and clinical history incompatible with a diagnosis of COPD (n=22), 20 
did not meet the definition for AECOPD (n=1), presented lung neoplasia (n= 2), severe 21 
heart failure (n=1), were unable to comply with testing (n=3), or decline to participate 22 
in the study (n=5). Forty-four non-hospitalised patients with AECOPD (31 males; 23 
68.2±9.1 years; 51.1±20.3 FEV1 percentage predicted) were invited and agreed to 24 
participate in the study. Nineteen patients were excluded from the respiratory sound 25 
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analysis because the respiratory sound data collection was not completed (n=6) and 1 
their respiratory sounds (collected at the urgent care) had a significant amount of 2 
background noise hindering the use of the algorithms described in the Data collection 3 
section (n=13). Participants’ characteristics are summarised in Table 2. 4 
Table 2. Sample characterisation. 5 
Characteristics Patients with  
AECOPD 
(n=44) 
Patients included for 
RS analysis 
(n=25) 
Age, years,  68.2±9.1 70.0±9.8 
Sex (male), n(%) 31 (70.5) 16 (47.1) 
BMI, kg/m2 25.9±4.8 26.7±4.9 
Smoking status, n(%) 
Current 
Former 
Never 
 
8 (18.2) 
22 (50.0) 
14 (31.8) 
 
4 (16.0) 
11 (44.0) 
10 (40.0) 
Packs/year  45.0 [22.0-67.3] 30.0 [15.0-70.0] 
Exacerbations/year, n(%) 
0 
1 
≥2 
 
8 (18.2) 
11 (25.0) 
25 (56.8) 
 
5 (20.0) 
5 (20.0) 
15 (60.0) 
FEV1, L 1.22±0.51 1.25±0.54 
FEV1, %predicted 51.1±20.3 54.2±20.6 
FEV1/FVC, % 50.5±13.6 51.7±13.8 
GOLD stages, n(%)   
A 6 (13.6) 4 (6.8) 
B 5 (11.4) 3 (5.1) 
C 5 (11.4) 5 (8.5) 
D 26 (59.1) 13 (22.0) 
Medication, n(%)   
Antibiotics 28 (65.1) 17 (70.8) 
Bronchodilators   
SABA 9 (20.9) 3 (12.5) 
SAMA 6 (14.0) 3 (12.5) 
SABA/SAMA combination 6 (14.0) 6 (25.0) 
LABA 5 (11.6) 3 (12.5) 
LAMA 22 (51.2) 13 (54.2) 
LABA/LAMA combination 5 (11.6) 2 (8.3) 
ICS 7 (16.3) 5 (20.8) 
ICS/LABA combination 27 (62.8) 16 (66.7) 
Xanthines 16 (37.2) 8 (33.3) 
LTRA 4 (9.3) 3 (12.5) 
Expectorants 20 (46.5) 12 (50) 
Oral Corticosteroids 9 (20.9) 5 (20.8) 
mMRC 1.0 [0.5-2.0] 1.0 [0.5-2.0] 
Values are presented as mean±standard deviation or median [interquartile range], unless otherwise stated. BMI, body mass index; FEV1, forced expiratory volume in one 6 
second (at stability); FVC, forced vital capacity (at stability); GOLD, global initiative for chronic obstructive lung disease; ICS, inhaled corticosteroids; LABA, long-acting 7 
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beta-agonists; LAMA, long-acting muscarinic antagonists; LTRA, leukotriene receptor antagonist; mMRC, modified British Medical Research Council questionnaire; SD, 1 
standard deviation; SABA, short-acting beta agonists; SAMA, short-acting muscarinic-antagonist. 2 
Minimal important difference 3 
Following the AECOPD, 31 patients improved beyond the MID of the CAT 4 
(mean difference of -10.7±5.3), 6 patients did not improve beyond the MID (mean 5 
difference of 6.2±3.2) and 7 failed to complete the post-AECOPD assessment. 6 
Outlier’s examination leads to the removal of three participants. No differences were 7 
found between included participants and outliers for their baseline characteristics 8 
(p>0.05). Distribution of scores in SpO2, MBS, mMRC, respiratory sounds, FEV1 and 9 
FEV1 percentage predicted for all participants and according to differences in CAT are 10 
presented in Table 3. 11 
Table 3. Mean scores at the onset of AECOPD (T1), after 45 days of AECOPD (T4) and mean change 12 
for the respiratory measurement by the COPD Assessment Score. 13 
 Exacerbation  
onset 
Stability  
post exacerbation 
Mean difference p-value 
ΔSpO2 92.6±2.6 94.0±2.7 1.3±2.5 0.004 
≥ 2 CAT 92.7±2.6 94.0±2.8 1.5±2.7  
<2 CAT 92.2±2.6 94.0±2.4 2.0±2.1  
ΔMBS 2.3±2.2 1.0±1.9 -1.3±2.1 0.001 
≥ 2 CAT 2.2±2.2 0.7±1.2 -1.5±2.1  
<2 CAT 2.8±2.6 2.4±3.9 -0.4±1.8  
ΔmMRC 2.6±1.0 1.4±1.0 -0.9±1.1 <0.001 
≥ 2 CAT 2.3±1.1 1.3±0.9 -1.1±0.9  
<2 CAT 1.8±0.8 2.4±2.0 0.4±0.6  
ΔInspiratory CR 1.4±1.6 0.7±1.0 -0.7±1.1 0.013 
≥ 2 CAT 1.4±1.7 0.6±0.8 -0.6±1.1  
<2 CAT 1.4±1.7 1.5±1.8 -1.0±1.1  
ΔExpiratory CR 1.3±2.0 0.3±6.5 -0.1±2.2 0.026 
≥ 2 CAT 1.1±1.7 0.3±0.7 -0.8±1.8  
<2 CAT 3.5±4.9 0.4±0.7 -3.5±4.9  
ΔInspiratory %Wh 8.1±13.7 2.0±5.8 -6.3±16.3 0.096 
≥ 2 CAT 7.6±14.3 2.3±6.2 -5.6±16.9  
<2 CAT 13.7±1.9 0.0±0.0 -13.7±1.9  
ΔExpiratory %Wh 16.2±8.4 8.4±17.0 -5.6±30.7 0.307 
≥ 2 CAT 17.6±23.6 6.9±15.9 -9.8±29.9  
<2 CAT 2.1±3.0 18.7±24.1 25.5±23.1  
FEV1 1.09±0.51 1.23±0.50 0.12±0.33 0.037 
≥ 2 CAT 1.11±0.53 1.30±0.50 0.16±0.34  
<2 CAT 0.98±0.43 0.86±0.28 -0.07±0.26  
FEV1% predicted 46.2±18.2 52.8±20.0 5.6±14.3 0.049 
≥ 2 CAT 48.2±18.8 56.5±19.2 6.9±14.9  
<2 CAT 36.3±10.7 32.4±10.2 -1.2±8.0  
11 
 
Values are presented as mean± standard deviation. %Wh, wheeze occupation rate; CAT, COPD assessment test; CR, crackle; FEV1 (L), forced expiratory volume in one 1 
second; MBS, modified Borg scale; mMRC, Modified British Medical Research Council questionnaire; SpO2 (%), peripheral oxygen saturation. 2 
Correlations with changes in CAT equal or superior to 0.3 were found for 3 
changes in MBS (r=0.34; p=0.05), mMRC (rs0.39; p=0.025) and FEV1 (r=-0.33; 4 
p=0.048) (Figure 1). No significant correlations were observed with changes in SpO2 5 
(r=-0.02; p=0.894), FEV1 percentage predicted (r=-0.29; p=0.102), inspiratory (r=-6 
0.21; p=0.356) and expiratory (r=-0.22; p=0.324) number of crackles, and inspiratory 7 
(r=0.24; p=0.291) and expiratory (r=0.36; p=0.102) wheeze occupation rate. 8 
Therefore, MID could only be calculated for MBS, mMRC and FEV1. 9 
 10 
Figure 1. Correlations between changes in the CAT and changes in the (A) modified Borg scale, (b) 11 
modified British Medical Research Council questionnaire (mMRC) and (C) forced expiratory volume in 12 
one second (FEV1). 13 
Using ROC statistics, the AUCs generated for the mMRC showed (AUC=0.92; 14 
95%CI=0.82–1.00; p=0.003) adequate discrimination between those improving above 15 
and below the MID for CAT (Figure 2). No significant results were observed for the 16 
discrimination ability of the MBS (AUC=0.63; 95%CI=0.37–0.89; p=0.366) and for the 17 
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FEV1 (AUC=0.67; 95%CI=0.43–0.90; p=0.243). Using ROC, a MID of -0.5 (SN=79%; 1 
SP=100%) was obtained for mMRC. Since significance was not reached for the MBS 2 
and FEV1, MID were not established.  3 
 4 
Figure 2. ROCs to discriminate between patients improving above and below the MID in CAT (i.e. two 5 
points) for the modified British Medical Research Council questionnaire (mMRC). 6 
Using linear regression, the estimated minimum important improvement for the 7 
MBS, mMRC and FEV1 was -0.8 (95% CI -1.65 to 0.00; p=0.05), -0.6 (95% CI -1.00 8 
to -0.22; p=0.025) and 0.03L (95% CI -0.11 to 0.17; p=0.049), respectively (Figure 3). 9 
13 
 
 1 
Figure 3. Linear regression between the CAT and the (A) modified Borg scale, (b) modified British 2 
Medical Research Council questionnaire (mMRC) and (C) FEV1. 3 
Minimal detectable difference 4 
Small effect sizes were found for the MBS (dz=0.37), FEV1 (dz=0.28), FEV1 5 
percentage predicted (dz=0.34), inspiratory number of crackles (dz=0.48) and 6 
expiratory wheeze rate (dz=0.39), medium effect sizes were found for the inspiratory 7 
wheeze rate (dz=0.58), expiratory number of crackles (dz=0.65) and SpO2 (dz=0.52) 8 
and large effect sizes were found for the mMRC (dz=0.80) (Table 4). Values of the 9 
0.5*SD, SEM and MDC95 can be found in the summary of Table 4. 10 
Pooled MID and MDD 11 
Pooled MID and MDD for the MBS, mMRC, FEV1, FEV1 percentage predicted, 12 
SpO2, inspiratory number of crackles, expiratory number of crackles, inspiratory 13 
wheeze rate and expiratory wheeze rate were of 0.9, 0.6, 0.15L, 7.6%, 1.5%, 1.1, 2.4, 14 
14.1% and 32.5%, respectively. Individual and pooled values can be found in Table 4 15 
and plots of pooled MID and MDD for MBS, mMRC, FEV1 can be found in Figure 4. 16 
14 
 
Table 4. Anchor-based and distribution-based estimates of the minimal important and detectable 1 
differences of the respiratory measures. 2 
 Anchor-based methods Distribution-based method Pooled 
value 
Measures ROC 
curve 
Linear 
regression 
analysis 
ES 0.5*SD SEM MDC95  
MBS - 0.8 0.37 1.1 0.5 1.4 0.9 
mMRC 0.5 0.6 0.80 0.5 0.4 1.2 0.6 
FEV1  0.03 0.28 0.3 0.1 0.3 0.15 
FEV1% 
predicted 
- - 0.34 9.1 3.6 10.1 7.6 
SpO2 - - 0.52 1.3 0.9 2.4 1.5 
Insp. CR - - 0.48 0.8 0.7 1.9 1.1 
Exp CR - - 0.65 1.1 1.6 4.5 2.4 
Insp. %Wh - - 0.58 7.1 9.3 25.8 14.1 
Exp. %Wh - - 0.39 11.8 22.7 63.0 32.5 
%Wh, wheeze occupation rate; CR, crackle; ES, effect size; FEV1, forced expiratory volume in one second; MBS, modified Borg scale; MDC95, minimal detectable change 3 
at the 95% level of confidence; mMRC, Modified British Medical Research Council questionnaire; ROC, receiver operating characteristic; SD, standard deviation; SEM, 4 
standard error of measurement; SpO2, peripheral oxygen saturation. Results are presented as absolute values. 5 
 6 
Figure 4. Summary plots of the pooled values of the MID and MDD for the (A) modified Borg scale; (B) 7 
modified British Medical Research Council (mMRC) questionnaire and (C) forced expiratory volume in 8 
one second (FEV1), percentage predicted. The horizontal plots represent the minimal clinically 9 
important difference estimates derived in this study, classified per method. Where appropriate the 10 
15 
 
estimates include the 95% confidence interval. The bold dotted vertical line resembles the MID estimate 1 
as obtained from the literature for stable patients with COPD. 2 
Discussion 3 
This study showed a pooled MID and MDD of 0.9 for the MBS, 0.6 for the 4 
mMRC, 0.15L for the FEV1, 7.6% for the FEV1 percentage predicted, 1.5% for the 5 
SpO2, 1.1 for inspiratory and 2.4 for the expiratory number of crackles, 14.1% for the 6 
inspiratory and 32.5% for the expiratory wheeze occupation rate.  7 
The pooled MID and MDD for dyspnoea scales were similar to those reported 8 
in pharmacological trials (approximately 1 point in the MBS) 45,46 and slightly lower 9 
than those reported for pulmonary rehabilitation and surgical intervention 10 
(approximately two points in the MBS and one point in the mMRC) 23 in stable patients 11 
with COPD. Large benefits of these last two interventions are quickly perceived and 12 
reported by patients, since they either target specifically dyspnoea (i.e., pulmonary 13 
rehabilitation) or are invasive and affect directly the mechanics of breathing (i.e., 14 
surgery), contrary to the effects of pharmacological treatments, which mainly target 15 
inflammation and/or infection 45. Attention to patients’ baseline dyspnoea and to the 16 
ability to change of the outcome measure is also needed when interpreting these data. 17 
MBS is not strictly linear, and having a sample with higher scores of dyspnoea 18 
(previous studies ranged from 1.8 to 8.5) than those reported in our study, will lead to 19 
larger changes, as at the higher end of the scale there are larger numerical intervals 20 
between word anchors for symptom severity 45. The mMRC presented large effect 21 
sizes following the recovery period of the AECOPD than in previous studies with stable 22 
patients, showing to be more sensitive to changes with interventions during AECOPD 23 
than in stable stages of the disease 23,46.  24 
Although the values of the MID and MDD are similar between disease stages, 25 
which facilitates their used interchangeably during stable and exacerbation periods, 26 
health professionals should be aware that the time needed to achieve these MID/MDD 27 
was shorter in patients with AECOPD (approximately 45 days), than the three months 28 
of treatments commonly used in stable patients 20,23,45.  29 
16 
 
Therefore, the nature of the interventions, patients’ baseline dyspnoea, the 1 
sensitivity to change of the measure used and the time until treatment effects are main 2 
aspects to consider when interpreting MID and MDD for dyspnoea scales. These novel 3 
results not only attribute meaning to patients’ improvements during AECOPD but will 4 
also aid health professionals to establish specific timings to follow-up dyspnoea 5 
symptoms in these patients.  6 
Similar to dyspnoea scales, the MID achieved for the FEV1 matched those 7 
reported in the literature for stable patients (0.10–0.18 litres) 47. Nevertheless, few 8 
studies have determined MID for the FEV1, mainly due to the lack of correlation 9 
between lung function and patient-reported outcomes 48,49 and because lung function 10 
is commonly not a goal in the management of COPD 11. Conversely, lung function is 11 
still the primary endpoint most frequently used by regulatory authorities to interpret 12 
drug efficacy in COPD trials 50 and spirometry has been found to be reliable and valid 13 
during AECOPD 12. Thus, our findings may be used in future clinical trials to establish 14 
therapies effectiveness during AECOPD, further contributing to the current health and 15 
research priority of finding the most appropriate management for AECOPD 6.  16 
Due to the lack of correlation with the anchor chosen, only MDD could be 17 
established for the FEV1 percentage predicted, SpO2 and respiratory sounds. These 18 
outcome measures have been extensively used to assess efficacy of interventions in 19 
patients with AECOPD, however little is known about their measurement properties 20 
and interpretability 7. There is only one recommendation from the European 21 
Respiratory Society to consider an increment of 9% in FEV1 percentage predicted for 22 
bronchodilator responsiveness in stable patients, which is identical to our results 51. 23 
A medium effect size was found for SpO2, after the intervention, meaning that 24 
SpO2 may be little sensitive to changes in outpatients with AECOPD. Although a MID 25 
could not be obtained, according to the oxyhaemoglobin dissociation curve, it would 26 
not be expected that a difference of 1.5% would be clinically significant for patients 27 
already presenting baseline SpO2 higher than 92%. Nevertheless, such difference 28 
might be meaningful in more hypoxemic patients, as it will make a difference in their 29 
ability to perform activities of daily living 52. Future studies including patients with 30 
different levels of baseline SpO2 are needed to further explore this hypothesis and 31 
establish recommendations for clinical practice. 32 
17 
 
Minimal detectable differences found for computerised respiratory sounds were 1 
lower than those previously published in stable patients (i.e., MDD of 2.4 for inspiratory 2 
crackles) 28, but significantly higher than the differences found before and after a 3 
pulmonary rehabilitation programme in stable patients (i.e., mean difference of 0.8 for 4 
expiratory crackles and median difference of less than 10% in inspiratory and 5 
expiratory %Wh) 53 and during the course of an AECOPD (mean difference of less 6 
than 1 crackle and less than 10% in inspiratory and expiratory number of crackles and 7 
%Wh, respectively) 15. These results imply that although statistically significant, the 8 
changes being observed in the literature may be within the error of the measure. 9 
Nevertheless, these interpretations need caution, as it is known that respiratory 10 
sounds present high intersubject variability 29, which have probably influenced the 11 
MDD obtained using distribution methods. 12 
Limitations and future work 13 
This study has some limitations that need to be acknowledged. Treatment of 14 
exacerbations was not standardised, but optimised according to the physician best 15 
judgement, using pharmacology as the standard treatment. Although the effects of 16 
therapies were not of interest in this study, it must be acknowledged that different 17 
combination of treatments might influence patient’s recovery. Additionally, MID could 18 
not be established for FEV1 percentage predicted, SpO2 and computerised respiratory 19 
sounds, which may reduce their usefulness to interpret clinical changes. These 20 
outcome measures have great potential to be used at bedside of patients with 21 
AECOPD, as they are simple non-invasive and widely available. Thus, it is important 22 
that future studies build knowledge from our results and find relevant anchors to 23 
establish MID for FEV1 percentage predicted, SpO2 and computerised respiratory 24 
sounds. Also, patient’s stable state prior to the exacerbation was not assessed, and 25 
thus it cannot be firmly stated that all patients have returned to their baseline 26 
symptoms as reported by themselves. However, as only outpatients, which present 27 
less severe exacerbations 11, were included, and no reports of relapses and changes 28 
in treatment occurred, we strongly believe that patients were in a stable state of their 29 
disease during the last data collection moment and that the established MID/MDD can 30 
be used with confidence. Although the most recommended anchor and distribution 31 
methods have been used to establish the MID and MDD, other important anchor 32 
methods 41,43, such as patient and health professional referencing, using global rate of 33 
18 
 
change scales and criterion-referencing, through correlation with key health-related 1 
events in COPD were not implemented. Thus, further examination of the 2 
interpretability of these respiratory measures is recommended, including using 3 
additional anchor methods but also establishing MID for different relevant interventions 4 
and patients with different levels of severity of their AECOPD. Finally, the sample 5 
included in this study is part of a primary research aiming at exploring the time-course 6 
of AECOPD in outpatients 15,54, thus a sample size calculation was not computed 7 
specifically to address the establishment of MID and MDD. This limitation may have 8 
caused our study to be underpowered for this aim. Nevertheless, according to the 9 
authors’ best knowledge, this is the first study to contribute to establish MID and MDD 10 
of several respiratory outcome measures used in the monitoring of patients with 11 
AECOPD, and thus it has potential to be used, not only in clinical practice, to aid 12 
clinical interpretations of responses to interventions, but also as a booster for future 13 
research in the area, by providing data to compute appropriate sample sizes. 14 
Conclusion 15 
Pooled data of MID and MDD showed that improvements of 0.9 for the MBS, 16 
0.6 for the mMRC, 0.15L for the FEV1, 7.6% for the FEV1 percentage predicted, 1.5% 17 
for the SpO2, 1.1 for the inspiratory and 2.4 for the expiratory number of crackles, 18 
14.1% for the inspiratory and 32.5% for the expiratory wheeze occupation rate are 19 
meaningful following an AECOPD managed with pharmacological treatment on an 20 
outpatient basis. These estimates might be useful in clinical practice to aid clinical 21 
interpretations of responses to interventions and to monitor recovery of outpatients 22 
with AECOPD. 23 
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